My Treatment Approach: Navigating First-Line Treatment Options in Locally Advanced and Metastatic Urothelial Cancer - Episode 5

Timeline of Enfortumab Vedotin in UC: From Previously Treated UC to Frontline Therapy

Thomas Powles, MBBS, MRCP, MD, discusses how antibody-drug conjugates have demonstrated improvement over chemotherapy. Data from the EV-301 trial shows that the antibody-drug conjugate enfortumab vedotin decreased the risk of death by 30% versus chemotherapy. Later trial data showed that treatment using enfortumab vedotin plus pembrolizumab (EV+P) reduced the risk of patient death by 53%.